ArticleASAIO journal (American Society for Artificial Internal Organs : 1992)2019
In Vivo 5 Day Animal Studies of a Compact, Wearable Pumping Artificial Lung.
Article in ASAIO journal (American Society for Artificial Internal Organs : 1992), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 36 citations in OpenAlex.
- Transplantation, bridging, and support technologies in pulmonary hypertension.The European respiratory journal · 2024Review
- Progress towards permanent respiratory support.Current opinion in organ transplantation · 2024Review
- Ambulatory 7-day mechanical circulatory support in sheep model of pulmonary hypertension and right heart failure.The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation · 2024Article
- Oxygenation performance assessment of an artificial lung in different central anatomic configurations.The International journal of artificial organs · 2023Article
- Seven-day in vivo testing of a novel, low-resistance, pumpless pediatric artificial lung for long-term support.Journal of pediatric surgery · 2022Article
- Article
- The Roles of Membrane Technology in Artificial Organs: Current Challenges and Perspectives.Membranes · 2021Review
- Advances in extracorporeal membrane oxygenator design for artificial placenta technology.Artificial organs · 2021Review
- Pediatric and neonatal extracorporeal life support: current state and continuing evolution.Pediatric surgery international · 2021Review
- In vivo testing of the low-flow COIntensive care medicine experimental · 2020Article
- Long-Term Venovenous Connection for Extracorporeal Carbon Dioxide Removal (ECCOCardiovascular engineering and technology · 2020Article
- Evaluation of an autoregulatory ECMO system for total respiratory support in an acute ovine model.Artificial organs · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
Abstract
Recent studies show improved outcomes in ambulated lung failure patients. Ambulation still remains a challenge in these patients. This necessitates development of more compact and less cumbersome respiratory support specifically designed to be wearable. The Paracorporeal Ambulatory Assist Lung (PAAL) is being designed for providing ambulatory support in lung failure patients during bridge to transplant or recovery. We previously published in vitro and acute in vivo results of the PAAL. This study further evaluates the PAAL for 5 days. Five-day in vivo studies with the PAAL were conducted in 50-60 kg sheep after heparinization (activated clotting time range: 190-250 s) and cannulation with a 27 Fr. Avalon Elite dual-lumen cannula. The animals were able to move freely in a stanchion while device flow, resistance, and hemodynamics were recorded hourly. Oxygenation and hemolysis were measured daily. Platelet activation, blood chemistry, and comprehensive blood counts are reported for preoperatively, on POD 0, and POD 5. Three animals survived for 5 days. No study termination resulted from device failure. One animal was terminated on POD 0 and one animal was terminated at POD 3. The device was operated between 1.93 and 2.15 L/min. Blood left the device 100% oxygenated. Plasma-free hemoglobin ranged 10.8-14.5 mg/dl. CD62-P expression was under 10%. Minimal thrombus was seen in devices at explant. Chronic use of the PAAL in awake sheep is promising based on our study. There were no device-related complications over the study course. This study represents the next step in our pathway to eventual clinical translation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.